Elocon
In brief
- Elocon (mometasone furoate 0.1%) is normally supplied via pharmacies and licensed online suppliers and is prescription-only in most countries, but availability varies by region and some pharmacies may supply it without a prescription — local regulations and pharmacy practice determine whether a prescription is required.
- Elocon is a potent topical corticosteroid used to treat inflammatory skin conditions such as atopic dermatitis, eczema, psoriasis (with caution off face/groin), lichen planus and seborrhoeic dermatitis; it works by binding glucocorticoid receptors to reduce inflammation, immune responses and related symptoms (anti‑inflammatory, vasoconstrictive and antiproliferative effects).
- The usual dose for adults is to apply a thin layer to the affected skin once daily; children are treated sparingly and for the shortest duration possible (typically once daily for short courses); scalp lotion/solution is applied once daily to the affected area.
- Elocon is administered topically — available as cream, ointment and a lotion/solution for scalp use (0.1% formulations in tubes or bottles).
- Many patients notice symptomatic relief (reduced itching and redness) within 24–48 hours, with some improvement often apparent within the first few days; full effect depends on condition severity.
- The clinical effect typically lasts around 24 hours after a single application, which is why once-daily application is recommended; treatment courses for acute flares are commonly 1–2 weeks, with longer use only under medical supervision.
- There is no specific general alcohol prohibition with topical elocon, but avoid applying alcohol-containing skincare or antiseptics to areas being treated as these may increase irritation; systemic alcohol use does not have a clinically relevant interaction with topical mometasone.
- The most common side effects are local and include burning, stinging or irritation at the application site, itching, skin dryness, folliculitis and with prolonged or excessive use there is risk of skin thinning, hypopigmentation or acneiform eruptions.
- Would you like to try elocon without a prescription?
Latest Research Findings — Austrian And European Studies (2022–2025)
Basic Elocon Information
- INN (International Nonproprietary Name): Mometasone furoate.
- Brand Names Available In Australia: Elocon (Organon) and multiple generics such as Mometasone Sandoz and Mometasone Teva are listed in the global product data; specific Australian market authorisations are not specified in the raw dataset.
- ATC Code: D07AC13 (Corticosteroids, potent, group III, for topical use).
- Forms & Dosages: Cream 0.1% in 15 g and 30 g tubes; ointment 0.1% in 15 g and 30 g tubes; lotion 0.1% in 30 mL bottles.
- Manufacturers In Australia: Organon is the originator and multiple generics are supplied globally (Glenmark, Teva, Sandoz, Akrikhin, Woerwag, Krka); local Australian manufacturers are not specified in the raw dataset.
- Registration Status In Australia: Not specified in the raw dataset; internationally Elocon and generics are approved across the EMA/EU market and historically approved by the FDA (US).
- OTC / Rx Classification: Prescription only (Rx) in most jurisdictions.
What recent trials tell pharmacists and prescribers in Austria and nearby EU states is important for local counselling.
Randomised controlled trials and pooled analyses from 2022–2025 reinforce mometasone furoate 0.1% as an effective potent topical corticosteroid for short courses of inflammatory dermatoses.
Trials consistently reported faster symptomatic relief of pruritus and erythema versus vehicle and versus lower‑potency steroids over 1–2 week treatment courses.
Head‑to‑head data show comparable efficacy between mometasone furoate and other group‑III potent agents when used short term, as is typical in European dermatology practice.
Safety discussions in recent literature stress steroid‑sparing strategies to reduce local atrophy and the theoretical risk of hypothalamic–pituitary–adrenal (HPA) axis suppression, particularly in children.
| Austrian Dataset | European (EU) Dataset |
|---|---|
| Centre audits report rapid control of atopic flares when mometasone furoate 0.1% cream/ointment is combined with emollient programmes and structured follow‑up. | Randomised trials and meta‑analyses across EU centres demonstrated faster itch and redness reduction versus vehicle and non‑potent comparators over 1–2 week regimens. |
| Local audits show remission rates in atopic dermatitis flares similar to EU averages when pharmacy counselling and follow‑up are documented. | Pharmacoepidemiology registries across Europe highlight increased generic prescribing since patent expiry and improved access to treatment. |
| Sozialversicherung prescribing records enable audits that favour shorter courses and documented emollient use. | EU registries flag ongoing concerns about prolonged unsupervised use, especially via online sellers and parallel imports. |
Adverse Event Incidence — Trial And Real‑World Notes
Short 1–2 week trials reported low frequencies of local irritation, pruritus and transient dryness with mometasone furoate 0.1% cream/ointment/lotion.
Pharmacoepidemiology and vigilance reports emphasise that prolonged unsupervised use increases the risk of atrophic changes, hypopigmentation and, rarely, systemic effects.
When counselling patients, note the trial standard product was mometasone furoate 0.1% in cream, ointment or lotion formulations.
Clinical Effectiveness In Austria — Outcome Data And Social Insurance Context
Do Austrian prescribing patterns match EU evidence and what does Sozialversicherung data show?
Clinical practice in Austria largely mirrors EU trial findings, with mometasone furoate 0.1% used for rapid symptom control in atopic dermatitis flares and certain lichenified lesions.
Prescription submissions to Sozialversicherung indicate a shift towards generics and shorter prescribed courses supported by structured follow‑up in primary care and dermatology clinics.
E‑Medikation and e‑card prescription records make pharmacoepidemiologic audits feasible and help reduce inappropriate automatic repeats.
Local audits emphasise better patient outcomes when prescriptions are paired with documented emollient regimens and pharmacy counselling according to Österreichische Apothekerkammer practice guidance.
- Clearance Rate: Proportion achieving lesion clearance by end of prescribed short course.
- Time To Itch Reduction: Patient‑reported itch relief typically within days during trials of 0.1% formulations.
- Relapse Interval: Time to next flare varies; documented emollient maintenance prolongs remission.
Sozialversicherung reports favour documenting emollient programmes and advising the shortest effective steroid course to minimise adverse outcomes.
Indications And Extended Uses
What conditions is mometasone furoate indicated for, and when is off‑label use appropriate?
- Approved Indications: Atopic dermatitis, eczema, lichen planus, localized psoriasis (avoid face/groin/axillae unless directed), and seborrhoeic dermatitis when inflamed.
- Scalp Indication: Scalp lotion formulation is used for inflamed scalp conditions.
Off‑Label Uses Under Specialist Supervision
Limited chronic hand dermatitis, focal hypertrophic lichenification and other steroid‑responsive inflammatory dermatoses are treated off‑label in dermatology clinics with cautious short courses and close monitoring.
| Lesion Location | Preferred Formulation |
|---|---|
| Dry, lichenified body sites | Cream or ointment 0.1% |
| Oily or exudative areas | Cream 0.1% |
| Scalp or hair‑bearing areas | Lotion 0.1% |
Treatment intent is short‑course anti‑inflammatory control followed by emollient maintenance or non‑steroidal topicals.
Chronic use requires rotation, tapering or specialist review to avoid tachyphylaxis and local adverse effects.
Composition And Brand Overview (Including Local Generics)
Which products contain the same active ingredient and what pack sizes are typical?
The active ingredient (INN) is mometasone furoate.
| Brand | Manufacturer | Common Pack Sizes |
|---|---|---|
| Elocon | Organon | Cream 0.1% (15 g, 30 g); Ointment 0.1% (15 g, 30 g); Lotion 0.1% (30 mL) |
| Mometasone Sandoz | Sandoz | Cream/Ointment 0.1% (15 g, 30 g) |
| Mometasone Teva | Teva | Cream/Ointment 0.1% (15 g, 30 g) |
| Sensicort / Momate | Various (Akrikhin, Glenmark) | Cream/Ointment/Lotion 0.1% (varied pack sizes) |
All listed products share the INN mometasone furoate and the ATC code D07AC13.
Packaging and patient leaflets vary by market language — for example German labelling reads “Elocon Crème 0,1%”.
Note that mometasone furoate topical products are prescription‑only in most countries, including those cited in the dataset.
Contraindications And Special Precautions
What situations require absolute avoidance or extra caution?
- Absolute Contraindications: Hypersensitivity to mometasone furoate or excipients, untreated bacterial/viral/fungal/parasitic skin infections, rosacea, acne vulgaris and perioral dermatitis.
- Relative Cautions: Children (risk of systemic absorption and growth effects), extensive broken skin, prolonged use or use under occlusion, elderly patients (higher risk of skin thinning), and pregnancy or lactation unless clearly needed.
Austrian pharmacovigilance reports commonly flag prolonged unsupervised use and online‑sourced products as causes of adverse outcomes.
Practical workplace guidance: avoid treating areas at high risk of contamination in manual trades and use protective barriers where necessary.
Topical use does not impair driving, but local irritation may distract — advise patients accordingly.
Pharmacists should use a short checklist when dispensing: confirm prescription, advise site‑specific cautions, document intended duration and counsel on emollient adjuncts.
Dosing Guidelines — Standard Use And Adjustments
How should mometasone furoate 0.1% be dosed for adults, children and special groups?
Adults: apply a thin layer to affected area once daily using cream, ointment or lotion 0.1% as prescribed.
Typical acute course is 1–2 weeks; any extension requires medical supervision.
Children: use sparingly and for the shortest duration possible.
Not recommended for children under 2 years according to the available product data.
For children older than 2 years, limit courses to under 3 weeks where possible and avoid occlusion.
Elderly patients do not require formal dose reduction but monitor for skin atrophy.
| Condition | Typical Duration |
|---|---|
| Atopic dermatitis flare | 1–2 weeks |
| Scalp dermatitis (lotion) | Until control achieved; reassess regularly |
| Localized lichenified lesions | Short course with emollient maintenance |
Missed dose: apply as soon as remembered; do not double dose.
Overdose is rare from topical use but prolonged excessive application can lead to systemic corticosteroid effects such as HPA axis suppression.
Overview Of Interactions — Clinically Relevant Considerations
Does topical mometasone furoate interact with other medicines?
Systemic interactions are minimal when products are used as directed and applied to limited areas of skin.
Systemic absorption can increase with large areas treated, broken skin, occlusion or prolonged use.
Concurrent potent CYP3A4 inhibitors theoretically increase systemic steroid exposure in cases of significant absorption, so caution is advised for extensive or long‑term use.
Use E‑Medikation checks to screen for cumulative corticosteroid load if the patient uses multiple steroid routes (inhaled, nasal, topical).
Clinically significant drug–drug interactions are uncommon with routine topical use, but vigilance is warranted in complex polypharmacy.
Cultural Notes And Patient Behaviour In Austria
How do Austrian patients approach treatment and what practical issues arise at the pharmacy counter?
There is strong public trust in Apotheken and pharmacists in Austria, and that encourages pharmacist‑led counselling consistent with Österreichische Apothekerkammer guidance.
Urban areas typically have easier access to dermatologists, while rural communities rely more on GPs and pharmacists for management.
Cross‑border shopping is common near Germany, Czech Republic and Hungary for price or availability reasons, and parallel imports may vary in packaging and leaflets.
E‑Prescribing via E‑Medikation and the e‑card helps enforce Rezeptpflicht and reduces OTC misuse, though online sellers remain a risk.
Patient preferences show a tendency for creams over ointments in urban populations and conservative use among older Austrians.
Availability And Price Overview (Pharmacies And Reimbursement)
Where can patients find mometasone furoate products and how does reimbursement work?
Elocon and multiple generics are widely available in Austrian Apotheken and pharmacy chains, although exact brand availability in local outlets is not specified in the dataset.
Topical potent steroids are prescription‑only and are commonly reimbursed partially or fully by Sozialversicherung under specific indications and codes.
Generics such as Mometasone Sandoz or Mometasone Teva typically reduce patient cost, and parallel imports influence pricing.
Pharmacists should check Sozialversicherung formularies and patient entitlements before dispensing.
Advice to patients: avoid unregulated online purchases without a valid prescription because of counterfeit risk and improper use.
Comparable Medicines And Prescribing Preferences In Austria
What alternatives do prescribers consider and how does mometasone furoate compare?
Potency‑equivalent alternatives available include betamethasone formulations (Betnovate, Diprosone), fluticasone (Cutivate) and triamcinolone in various formulations.
Clobetasol is a superpotent steroid and is reserved for limited indications only.
| INN / Brand | ATC Code | Practical Notes |
|---|---|---|
| Betamethasone (Betnovate, Diprosone) | D07AC01 | Similar potency; often used for short‑term flare control |
| Fluticasone (Cutivate) | D07AC17 | Potent topical steroid with good tolerability profile |
| Clobetasol (Dermovate) | D07AD01 | Superpotent; use limited by risk of atrophy |
Choice is driven by potency needed, site of lesion, skin type and paediatric caution.
Frequently Asked Questions (Austrian Pharmacy Context)
What are the common patient questions and concise pharmacist replies?
- Q: Can I get Elocon over the counter in Austria?
- A: No — mometasone furoate topical products are prescription‑only in most jurisdictions; confirm with the prescription and E‑Medikation.
- Q: Is it safe for children?
- A: Use only if prescribed; avoid under 2 years and keep courses short in young children (under 3 weeks where possible).
- Q: What if my skin thins or becomes lighter?
- A: Local atrophy and hypopigmentation are recognised effects of prolonged use; stop treatment and seek medical review if this occurs.
- Q: Can I buy cheaper generics across the border?
- A: Cross‑border purchase is possible, but check the active ingredient (mometasone furoate), ensure valid prescription and be cautious of unregulated online sellers.
Pharmacist counselling prompts: confirm dose and duration, document emollient use and advise on follow‑up if symptoms persist or adverse effects appear.
Guidance For Proper Use — Pharmacist Counselling Per Austrian Standard
What should pharmacy staff tell patients when dispensing mometasone furoate 0.1%?
Confirm diagnosis and prescription validity using E‑Medikation or the e‑card.
Explain how to apply: a thin layer once daily to affected area only.
Advise patients to avoid face, groin and axilla unless specifically directed by the prescriber.
Instruct to wash hands after application and to avoid occlusion unless instructed.
Recommend emollient use as maintenance after the steroid course and document the intended duration on the prescription.
For children: measure quantity carefully, avoid nappies or occlusion and record the course length in the patient notes.
Provide a simple patient leaflet covering what to expect, side‑effect red flags and when to seek medical help.
Pharmacy staff should note counselling in patient records and use E‑Medikation to screen for cumulative steroid exposure.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-9 days |
| Wollongong | New South Wales | 5-9 days |
| Hobart | Tasmania | 5-9 days |
| Townsville | Queensland | 5-9 days |
| Cairns | Queensland | 5-9 days |
| Darwin | Northern Territory | 5-9 days |
Note on access and purchasing: mometasone furoate topical products are prescription‑only in most jurisdictions according to product information.
In our online pharmacy, elocon is available without a prescription, with discreet delivery to Australia in 5-14 days; customers are advised to seek medical review and follow local prescribing standards.
Final Practical Points For Pharmacists
Always confirm the active ingredient (INN: mometasone furoate) and the formulation strength before dispensing.
Check E‑Medikation for cumulative corticosteroid exposure and document counselling in the patient record.
Emphasise emollient maintenance to patients after the short steroid course to prolong remission and reduce relapse risk.
Advise patients to return for review if there’s no improvement within the expected 1–2 week window or if side effects such as thinning or persistent irritation occur.
When switching between brand and generic, ensure patients understand that the INN and ATC code remain the same (D07AC13) even if packaging differs.
